SCHEMBL22143751

SCHEMBL22143751

O[C@@H]1CCOc2c(F)cc(F)cc21

nearest known ligand 0.42

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MAP3K14 Q99558 2/20 0.40
HTR1A P08908 2/20 0.33
PARP1 P09874 1/20 0.33
ADRA2A P08913 1/20 0.32
P2RX7 Q99572 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25352751 1.00 MAP3K14 (0.40) MAP3K14HTR1APARP1ADRA2AP2RX7
SCHEMBL31357918 0.81
SCHEMBL1266174 0.79 KDM1A (0.33) PARP1ADRA2A
SCHEMBL25351934 0.79 ADRA2A (0.32) ADRA2A
SCHEMBL22143867 0.79 PGR (0.33) ADRA2A
SCHEMBL24593733 0.79 PGR (0.33) ADRA2A
SCHEMBL12926173 0.79 KDM1A (0.33) PARP1ADRA2A
SCHEMBL3988257 0.79 KDM1A (0.33) PARP1ADRA2A
Hydrochloric Acid SCHEMBL1265324 0.77 KDM1A (0.33) PARP1ADRA2A
SCHEMBL22143945 0.75 ADRA2A (0.50) MAP3K14HTR1AADRA2AP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11377425-B1 Small molecule modulators of IL-17 LEO PHARMA A/S (DK) 2022-07-05 US disclosed
WO-2020127685-A1 AMINO-ACID ANILIDES AS SMALL MOLECULE MODULATORS OF IL-17 LEO PHARMA A/S (DK) 2020-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11377425-B1 Small molecule modulators of IL-17 IL17A, IL15, IL2 MAP3K14 707/4885HTR1A 3046/4885PARP1 4301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.